Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Fox Corp Class A (FOXA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Fox Corp Class A — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $225 (market cap $29.97B), while Fox Corp Class A trades at $62.43 (market cap $24.90B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Fox Corp Class A pays a 0.92% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | FOXA | |
|---|---|---|
Market Cap | $29.97B | $24.90B |
Sector | Health | Media |
52-Week High | $491.22 | $76.11 |
52-Week Low | $205.48 | $48.79 |
Enterprise Value | $27.93B | $28.26B |
Dividend Yield | — | 0.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
FOXA trades at $63.05, down 0.58% today, with a bullish technical outlook and strong fundamental performance. The stock shows consistent earnings beats, with Q2 2026 EPS of $1.79 surpassing the $1.44 estimate, and revenue growth from $14.0B in 2024 to $16.3B in 2025. Recent news highlights World Cup-driven ad revenue and Tubi streaming growth as key catalysts.
The outlook is positive with a $65.33 consensus price target and 50% analyst buy ratings, but risks include declining 2026 net income projections and high RSI levels suggesting overbought conditions. The stock offers value with a P/E of 16.18 and robust cash flow, though investors should monitor sports cost pressures and debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Fox Corp Class A
Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.
Read more on FOXA →
